Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 8.7% – Time to Sell?

Palvella Therapeutics, Inc. (NASDAQ:PVLA)’s stock price dropped 8.7% on Friday . The stock traded as low as $122.65 and last traded at $124.7450. Approximately 376,032 shares were traded during trading, an increase of 19% from the average daily volume of 317,032 shares. The stock had previously closed at $136.60.

Wall Street Analysts Forecast Growth

PVLA has been the subject of several analyst reports. Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. HC Wainwright upped their target price on shares of Palvella Therapeutics from $200.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Raymond James Financial reissued a “strong-buy” rating and issued a $193.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. UBS Group restated a “buy” rating and issued a $143.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Finally, Stifel Nicolaus set a $250.00 price objective on Palvella Therapeutics in a research note on Tuesday, February 24th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $184.87.

Palvella Therapeutics Trading Down 10.6%

The firm’s fifty day moving average price is $100.32 and its 200-day moving average price is $85.47. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -46.41 and a beta of -0.30.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total value of $420,004.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George M. Jenkins purchased 4,000 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, for a total transaction of $500,000.00. Following the transaction, the director owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC lifted its stake in Palvella Therapeutics by 8.5% in the fourth quarter. Suvretta Capital Management LLC now owns 892,400 shares of the company’s stock valued at $93,408,000 after buying an additional 70,000 shares in the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after acquiring an additional 32,388 shares in the last quarter. First Light Asset Management LLC raised its holdings in shares of Palvella Therapeutics by 30.9% during the fourth quarter. First Light Asset Management LLC now owns 709,141 shares of the company’s stock worth $74,226,000 after acquiring an additional 167,597 shares during the period. Vanguard Group Inc. lifted its position in Palvella Therapeutics by 13.3% in the 4th quarter. Vanguard Group Inc. now owns 560,616 shares of the company’s stock valued at $58,680,000 after acquiring an additional 65,960 shares in the last quarter. Finally, State Street Corp lifted its position in Palvella Therapeutics by 206.3% in the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after acquiring an additional 283,211 shares in the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.